909
Views
18
CrossRef citations to date
0
Altmetric
Review Article

Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?

&
Pages 379-386 | Received 19 Mar 2014, Accepted 25 May 2014, Published online: 30 Jan 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Andreas Stallmach, Carsten Schmidt & Niels Teich. (2016) Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 10:2, pages 165-175.
Read now

Articles from other publishers (17)

Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi & Byong Duk Ye. (2023) Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intestinal Research 21:1, pages 137-147.
Crossref
Javier P. Gisbert & María Chaparro. (2021) Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. Journal of Clinical Medicine 10:22, pages 5318.
Crossref
María Chaparro, Ana Garre, Marisa Iborra, Mónica Sierra-Ausín, Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Luisa de Castro, Maia Boscá-Watts, María José Casanova, Alicia López-García, Rufo Lorente, Cristina Rodríguez, Ana Y Carbajo, Maria Teresa Arroyo, Ana Gutiérrez, Joaquín Hinojosa, Teresa Martínez-Pérez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Cañete, Noemí Manceñido, David Monfort, Mercè Navarro-Llavat, José Lázaro Pérez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene García-de-la-Filia, Carlos González-Muñoza, Luis Hernández, José M Huguet, Víctor J Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suárez Álvarez, Cristina Calviño-Suárez, Elena Ricart, Vicent Hernández, Miguel Mínguez, Lucía Márquez, Daniel Hervías Cruz, Saioa Rubio Iturria, Jesús Barrio, Carla Gargallo-Puyuelo, Rubén Francés, Esther Hinojosa, María del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Mañosa, Ramón Pajares, Marta Piqueras, Orlando García-Bosch, Pilar López Serrano, Beatriz Castro, Alfredo J Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther García-Planella, David A Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domènech & Javier P Gisbert. (2021) Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. Journal of Crohn's and Colitis 15:11, pages 1846-1851.
Crossref
Ahmad Albshesh, Joshua Taylor, Edoardo V. Savarino, Marie Truyens, Alessandro Armuzzi, Davide G. Ribaldone, Ariella Bar-Gil Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancey, Mohamed Korani, Mariann Rutka, Manuel Barreiro-de Acosta, Viktor Domislovic, Gerard Suris, Carl Eriksson, Catarina Alves, Afroditi Mpitouli, Caroline di Jiang, Katja Tepeš, Marina Coletta, Kalliopi Foteinogiannopoulou, Javier P. Gisbert, Hadar Amir-Barak, Mohamed Attauabi, Jakob Seidelin, Waqqas Afif, Carla Marinelli, Triana Lobaton, Daniela Pugliese, Nitsan Maharshak, Anneline Cremer, Jimmy K. Limdi, Tamás Molnár, Borja Otero-Alvarin, Zeljko Krznaric, Fernando Magro, Konstantinos Karmiris, Tim Raine, David Drobne, Ioannis Koutroubakis, Maria Chaparro, Henit Yanai, Johan Burisch & Uri Kopylov. (2021) Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine 10:13, pages 2914.
Crossref
Tiantian Hu, Yang Fan, Xingyao Long, Yanni Pan, Jianfei Mu, Fang Tan & Xin Zhao. (2021) Protective effect of Lactobacillus plantarum YS3 on dextran sulfate sodium‐induced colitis in C57BL/6J mice . Journal of Food Biochemistry 45:2.
Crossref
Vince B C Biemans, Andrea E van der Meulen - de Jong, Christine J van der Woude, Mark Löwenberg, Gerard Dijkstra, Bas Oldenburg, Nanne K H de Boer, Sander van der Marel, Alexander G L Bodelier, Jeroen M Jansen, Jeoffrey J L Haans, Rosaline Theeuwen, Dirk de Jong, Marie J Pierik & Frank Hoentjen. (2020) Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis 14:1, pages 33-45.
Crossref
María José Casanova, María Chaparro, Miguel Mínguez, Elena Ricart, Carlos Taxonera, Santiago García-López, Jordi Guardiola, Antonio López-San Román, Eva Iglesias, Belén Beltrán, Beatriz Sicilia, María Isabel Vera, Joaquín Hinojosa, Sabino Riestra, Eugeni Domènech, Xavier Calvet, José Lázaro Pérez-Calle, María Dolores Martín-Arranz, Xavier Aldeguer, Montserrat Rivero, David Monfort, Jesús Barrio, María Esteve, Lucía Márquez, Rufo Lorente, Esther García-Planella, Luisa de Castro, Fernando Bermejo, Olga Merino, Antonio Rodríguez-Pérez, Pilar Martínez-Montiel, Manuel Van Domselaar, Guillermo Alcaín, Manuel Domínguez-Cajal, Carmen Muñoz, Fernando Gomollón, Luis Fernández-Salazar, Mariana Fe García-Sepulcre, Iago Rodríguez-Lago, Ana Gutiérrez, Federico Argüelles-Arias, Cristina Rodriguez, Gloria Esther Rodríguez, Luis Bujanda, Jordina Llaó, Pilar Varela, Laura Ramos, José María Huguet, Pedro Almela, Patricia Romero, Mercè Navarro-Llavat, Águeda Abad, Patricia Ramírez-de la Piscina, Alfredo J Lucendo, Eva Sesé, Rosa Eva Madrigal, Mara Charro, Antonio García-Herola, Ramón Pajares, Sam Khorrami & Javier P Gisbert. (2019) Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases.
Crossref
Ming-Hsi Wang, Jessica J Friton, Laura E Raffals, Jonathan A Leighton, Shabana F Pasha, Michael F Picco, Kelly C Cushing, Kelly Monroe, Billy D Nix, Rodney D Newberry & William A Faubion. (2019) Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 13:8, pages 1036-1043.
Crossref
Kelly Ribeiro Moura Barboza, Larissa Zambom Coco, Gisele Maziero Alves, Beatriz Peters, Elisardo Corral Vasquez, Thiago Melo Costa Pereira, Silvana Santos Meyrelles & Bianca Prandi Campagnaro. (2018) Gastroprotective effect of oral kefir on indomethacin-induced acute gastric lesions in mice: Impact on oxidative stress. Life Sciences 209, pages 370-376.
Crossref
Kindra Clark-Snustad, Ives Hot & Scott Lee. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics 13 32 .
Heba Iskandar, Julia B. Greer, Alyssa M. Krasinskas, Andrew T. Tinsley, Walter A. Koltun, Corey A. Siegel, L. Campbell Levy, Hans H. Herfarth, Francis A. Farraye, David G. Binion, Joel R. Rosh, David J. Keljo, Kim L. Isaacs & Miguel D. Regueiro. (2017) IBD LIVE Series—Case 8. Inflammatory Bowel Diseases 23:10, pages 1667-1677.
Crossref
Carlos Taxonera, Cristina Rodríguez, Federico Bertoletti, Luís Menchén, Julia Arribas, Mónica Sierra, Lara Arias, Pilar Martínez-Montiel, Alba Juan, Eva Iglesias, Alicia Algaba, Noemí Manceñido, Montserrat Rivero, Manuel Barreiro-de Acosta, Pilar López-Serrano, Federico Argüelles-Arias, Ana Gutierrez, David Busquets, Javier P. Gisbert, David Olivares, Marta Calvo & Cristina Alba. (2017) Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases 23:8, pages 1394-1402.
Crossref
Sine Buhl, Casper Steenholdt, Maria Rasmussen, Märta K. Borghede, Jørn Brynskov, Ole Ø. Thomsen & Mark A. Ainsworth. (2017) Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 23:7, pages 1210-1217.
Crossref
Konstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, Niels Vande Casteele, Ann Gils, Marc Ferrante, Gert Van Assche, Paul J. Rutgeerts, Gerassimos J. Mantzaris, Laurent Peyrin-Biroulet & Severine Vermeire. (2016) Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Journal of Crohn's and Colitis 10:9, pages 1015-1023.
Crossref
Hanaa Zbakh, Elena Talero, Javier Avila, Antonio Alcaide, Carolina de los Reyes, Eva Zubía & Virginia Motilva. (2016) The Algal Meroterpene 11-Hydroxy-1′-O-Methylamentadione Ameloriates Dextran Sulfate Sodium-Induced Colitis in Mice. Marine Drugs 14:8, pages 149.
Crossref
Sam Khorrami, Daniel Ginard, Ignacio Mar?n-Jim?nez, Mar?a Chaparro, M?nica Sierra, Mariam Aguas, Beatriz Sicilia, Valle Garc?a-S?nchez, Cristina Suarez, Albert Villoria, Carlos Taxonera, Antonio Velasco-Guardado, Javier Mart?nez-Gonz?lez & Javier P. Gisbert. (2016) Ustekinumab for the Treatment of Refractory Crohn?s Disease. Inflammatory Bowel Diseases 22:7, pages 1662-1669.
Crossref
Javier P. Gisbert & Eugeni Domènech. (2015) Vedolizumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 38:5, pages 338-348.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.